Alexandra Sumner on Muck Rack

Alexandra Sumner

Chicago
As seen in: Business Insider, MSN India, International Association of Privacy Professionals, Bloomberg Law, Business Insider Japan, GoodRx Blog, Bloomberg Tax, National Jurist

Get in touch with Alexandra

Contact Alexandra, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

The SECURE Data Privacy Bill Is Worth Reading, Even If It Dies Original

|
By Alexandra Sumner
| Bloomberg Law Verified
Federal privacy legislation has spent a decade stuck in the same loop: A bill drops, a hearing happens, the draft stalls, and companies go back to stitching compliance programs across the patchwork of state laws. What we’re left with is a quilt stitched by 20 different hands with no two squares quite lining up. Into that frayed picture comes the Securing and Establishing Consumer Uniform Rights and Enforcement over Data Act, or SECURE Data Act, introduced last month by Rep. John Joyce (R-Pa.).
Open in Who Shared View Duplicates (2) Issue with article?

When health data lives everywhere: Rethinking privacy outside the EHR

|
By Alexandra Sumner
| International Association of Privacy Professionals
For years, health privacy programs operated on a simple assumption: health data lives in medical records, and the U.S. Health Insurance Portability and Accountability Act tells us how to protect it. That assumption no longer reflects how care works. Today, the patient journey often starts online. People book appointments through third-party platforms, browse condition-specific webpages, use symptom checkers, chat with support teams and even receive text reminders.
Open in Who Shared Issue with article?

FDA Eases Wellness Device Regulation, But Marketing Is Still Key Original

|
By Alexandra Sumner
| Bloomberg Law Verified
The Food and Drug Administration’s decision to ease oversight of general wellness devices and certain artificial intelligence-driven software is designed to accelerate innovation and provide predictability for developers. But it also redraws a critical regulatory boundary. Many products that collect and analyze sensitive biometric data will now fall outside FDA review as long as they avoid explicit medical claims.
Open in Who Shared View Duplicates (3) Issue with article?
See all 69 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified